BOULDER, Colo., May 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2017 and hold a conference call to discuss those results on Wednesday, May 10, 2017. Ron Squarer, Chief Executive Officer, will lead the call.
Date: | Wednesday, May 10, 2017 |
Time: | 9:00 a.m. Eastern Time |
Toll-Free: | (844) 464-3927 |
Toll: | (765) 507-2598 |
Pass Code: | 92608803 |
Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/hgm92o9w
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven registration studies are currently advancing related to seven drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology), tucatinib (partnered with Cascadian Therapeutics) and ipatasertib (partnered with Roche).
CONTACT: | Tricia Haugeto |
Array BioPharma Inc. | |
(303) 386-1193 | |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2017-on-may-10-2017-300450284.html
SOURCE Array BioPharma
